Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer

The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting programmed cell death protein-1 (PD-1) and durvalumab, avelumab, and atezolizumab targeting PD-ligand 1 (PD-L1). Ipilimumab targets cytot...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapoport, Bernardo L., Shannon, Vickie R., Cooksley, Tim, Johnson, Douglas B., Anderson, Lindsay, Blidner, Ada G., Tintinger, Gregory R., Anderson, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523897/
https://www.ncbi.nlm.nih.gov/pubmed/34675810
http://dx.doi.org/10.3389/fphar.2021.743582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523897/
https://www.ncbi.nlm.nih.gov/pubmed/34675810
http://dx.doi.org/10.3389/fphar.2021.743582

Ejemplares similares